BRPI0516470A - uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase - Google Patents

uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase

Info

Publication number
BRPI0516470A
BRPI0516470A BRPI0516470-2A BRPI0516470A BRPI0516470A BR PI0516470 A BRPI0516470 A BR PI0516470A BR PI0516470 A BRPI0516470 A BR PI0516470A BR PI0516470 A BRPI0516470 A BR PI0516470A
Authority
BR
Brazil
Prior art keywords
type
psoriasis
prevention
treatment
interferon
Prior art date
Application number
BRPI0516470-2A
Other languages
English (en)
Inventor
Michel Gilliet
Frank O Nestle
Original Assignee
Universitot Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitot Zuerich filed Critical Universitot Zuerich
Publication of BRPI0516470A publication Critical patent/BRPI0516470A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

USO DE UM AGENTE DE BLOQUEIO DO INTERFERON TIPO 1, E, MéTODO DE PREVENçãO E TRATAMENTO DA PSORìASE. A descoberta dos precursores das células dendríticas plasmacitóides (PDC) como células efetoras cruciais com alta produção dos interferons (IFNs) tipo 1 no desenvolvimento prematuro da psoríase, levou à presente invenção de acordo com a qual esse bloqueio dos IFNs tipo 1 pode ser usado para a prevenção e terapia da psoríase. A invenção diz respeito ao uso de um agente de bloqueio do interferon tipo 1, tal como um antagonista do IFN tipo 1 (por exemplo, um anticorpo anti-IFN-<244> ou antagonista do receptor do IFN tipo 1, para a preparação de um medicamento para a prevenção e tratamento da psoríase, e a um método de prevenção e tratamento da psoríase com o uso de um agente de bloqueio do interferon tipo 1.
BRPI0516470-2A 2004-10-07 2005-09-30 uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase BRPI0516470A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04405628 2004-10-07
PCT/CH2005/000566 WO2006037247A1 (en) 2004-10-07 2005-09-30 Type i interferon blocking agents for prevention and treatment of psoriasis

Publications (1)

Publication Number Publication Date
BRPI0516470A true BRPI0516470A (pt) 2008-09-09

Family

ID=35593663

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516470-2A BRPI0516470A (pt) 2004-10-07 2005-09-30 uso de um agente de bloqueio do interferon tipo i, e, método de prevenção e tratamento da psorìase

Country Status (15)

Country Link
US (1) US20090155286A1 (pt)
EP (2) EP2286835A1 (pt)
JP (1) JP2008515819A (pt)
KR (1) KR20070083809A (pt)
CN (1) CN101056654A (pt)
AU (1) AU2005291741B2 (pt)
BR (1) BRPI0516470A (pt)
CA (1) CA2582471A1 (pt)
IL (1) IL182087A0 (pt)
MX (1) MX2007003809A (pt)
NO (1) NO20072024L (pt)
NZ (1) NZ554065A (pt)
RU (2) RU2007116988A (pt)
WO (1) WO2006037247A1 (pt)
ZA (1) ZA200702794B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4394350B2 (ja) 2001-01-09 2010-01-06 ベイラー リサーチ インスティテュート 対象における自己免疫疾患の治療法及びｉｎｖｉｔｒｏ診断アッセイ
US7888481B2 (en) 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
EP1851248B1 (en) * 2005-02-10 2016-08-10 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
ES2549903T3 (es) * 2008-05-07 2015-11-03 Argos Therapeutics, Inc. Anticuerpos humanizados contra interferón alfa humano
FR2968561B1 (fr) * 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
EP2623978A1 (en) 2012-02-03 2013-08-07 Charité - Universitätsmedizin Berlin CD8+ T-cell subsets as markers for prediction of delayed fracture healing
CN103319608B (zh) * 2013-07-01 2014-08-27 江苏众红生物工程创药研究院有限公司 猪IFNɑ1-Fc融合蛋白及其编码基因和表达方法
WO2015095143A1 (en) * 2013-12-16 2015-06-25 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
CN109535254B (zh) * 2013-12-24 2022-06-24 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
MA45554A (fr) 2016-07-01 2019-05-08 Resolve Therapeutics Llc Fusions de binucléase optimisées.
CN111315767B (zh) 2017-08-22 2025-03-18 萨纳生物有限责任公司 可溶性干扰素受体及其用途
AU2019276776B2 (en) * 2018-06-01 2025-12-11 ILC Therapeutics Limited Compositions and methods relating to the treatment of diseases

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4423147A (en) * 1980-04-11 1983-12-27 Secher David S Monoclonal antibody to interferon-α
US4824432A (en) * 1981-03-24 1989-04-25 S.V.S. Laboratories, Inc. Method for treating AIDS and other immune deficiencies and immune disorders
US4605394A (en) * 1982-12-03 1986-08-12 Simon V. Skurkovich Methods for the treatment of pathological conditions by removing interferon from the organism
US4362155A (en) * 1981-03-24 1982-12-07 Skurkovich Simon V Method and apparatus for the treatment of autoimmune and allergic diseases
DE3211263A1 (de) * 1981-03-31 1983-01-27 Otsuka Pharmaceutical Co. Ltd., Tokyo Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung
JPS60500864A (ja) * 1983-02-04 1985-06-06 ワドリ、テクナラジズ、インコーパレイティド 近縁関係にあるが別個のタンパク質間に存在する共通決定基に対して特異的なハイブリド−マ抗体の製造および特性づけ
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
FR2560212B1 (fr) * 1984-02-24 1989-12-29 Unicet Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps
EP0563487A1 (en) * 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation
DE19919149A1 (de) 1999-04-27 2000-11-16 Wieser Raimund J Von Interferon alpha-2 abgeleitete Peptid-Homodimere und Peptid-Heterodimere
JP5007007B2 (ja) * 1999-11-15 2012-08-22 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞
GB0001710D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic treatment
GB0001712D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
US6846486B1 (en) * 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
JP4394350B2 (ja) * 2001-01-09 2010-01-06 ベイラー リサーチ インスティテュート 対象における自己免疫疾患の治療法及びｉｎｖｉｔｒｏ診断アッセイ
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AU2003295471B2 (en) * 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25
PT2418220T (pt) * 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
EP1851248B1 (en) * 2005-02-10 2016-08-10 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use

Also Published As

Publication number Publication date
US20090155286A1 (en) 2009-06-18
AU2005291741B2 (en) 2011-11-24
NO20072024L (no) 2007-04-26
MX2007003809A (es) 2007-09-12
EP2286835A1 (en) 2011-02-23
IL182087A0 (en) 2007-07-24
NZ554065A (en) 2010-12-24
WO2006037247A1 (en) 2006-04-13
RU2007116988A (ru) 2008-11-20
RU2010146161A (ru) 2012-05-20
AU2005291741A1 (en) 2006-04-13
EP1796722A1 (en) 2007-06-20
CA2582471A1 (en) 2006-04-13
JP2008515819A (ja) 2008-05-15
ZA200702794B (en) 2008-06-25
KR20070083809A (ko) 2007-08-24
CN101056654A (zh) 2007-10-17

Similar Documents

Publication Publication Date Title
Ravikirti et al. Ivermectin as a potential treatment for mild to moderate COVID-19–a double blind randomized placebo-controlled trial
BR112021026580A2 (pt) Conjugado anticorpo - fármaco, intermediário do mesmo, método de preparação e aplicação do mesmo
Cegolon et al. Hypothesis to explain the severe form of COVID-19 in Northern Italy
Muscle Study Group* Randomized pilot trial of βINF1a (Avonex) in patients with inclusion body myositis
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
ATE361758T1 (de) Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
PT99108A (pt) Processo de preparacao de uma composicao farmaceutica a base de portadores naoaquosos de perfluorocarbonetos ou silicone fluorado
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BR0312947A (pt) terapias para insuficiência renal empregando-se interferon-beta
Manns et al. Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase II b and III studies
BR9807112A (pt) Composição, formulação farmacêutica, combinação e uso relacionados ao tratamento de doenças autoimunes utilizando antìgeno ou agente tolerante em combinação com metotrexato
Schiroky et al. Triazine compound as copolymerized antibacterial agent in adhesive resins
Bastyr III et al. Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure
Zheng et al. A novel protein drug, novaferon, as the potential antiviral drug for COVID-19
Jamaati et al. Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID‐19 in the Omicron variant era: A national cohort study in Iran
Nowak et al. Effects of combined modality therapy of head and neck carcinoma on shoulder and head mobility
Sulkowski et al. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection
Shemer et al. Clinical comparison and complete cure rates of terbinafine efficacy in affected onychomycotic toenails
BR0110512A (pt) Preparação para medir a taxa de esvaziamento gástrico
James Nitrous oxide: still useful in the year 2000?
BR0212917A (pt) Método para tratamento de infecção de vìrus da hepatite c em pacientes que não responderam a tratamento
EP3295934A1 (en) Antiviral pharmaceutical composition for topical use
Moriguchi et al. Treatment of SARS with human interferons
Mita et al. Real-world safety and effectiveness of 24-week sofosbuvir and ribavirin treatment in patients infected with rare chronic hepatitis C virus genotypes 3, 4, 5, or 6 in Japan
Janniger et al. Erythroderma as the initial presentation of the acquired immunodeficiency syndrome

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.